Jennifer B Stott1, Vincenzo Barrese1, Iain A Greenwood2. 1. From the Vascular Biology Research Group, Institute for Cardiovascular and Cell Sciences, St George's University of London, UK. 2. From the Vascular Biology Research Group, Institute for Cardiovascular and Cell Sciences, St George's University of London, UK. grenwood@sgul.ac.uk.
Abstract
OBJECTIVE: To establish the role of Kv7 channels in EPAC (exchange protein directly activated by cAMP)-dependent relaxations of the rat vasculature and to investigate whether this contributes to β-adrenoceptor-mediated vasorelaxations. APPROACH AND RESULTS: Isolated rat renal and mesenteric arteries (RA and MA, respectively) were used for isometric tension recording to study the relaxant effects of a specific EPAC activator and the β-adrenoceptor agonist isoproterenol in the presence of potassium channel inhibitors and cell signaling modulators. Isolated myocytes were used in proximity ligation assay studies to detect localization of signaling intermediaries with Kv7.4 before and after cell stimulation. Our studies showed that the EPAC activator (8-pCPT-2Me-cAMP-AM) produced relaxations and enhanced currents of MA and RA that were sensitive to linopirdine (Kv7 inhibitor). Linopirdine also inhibited isoproterenol-mediated relaxations in both RA and MA. In the MA, isoproterenol relaxations were sensitive to EPAC inhibition, but not protein kinase A inhibition. In contrast, isoproterenol relaxations in RA were attenuated by protein kinase A but not by EPAC inhibition. Proximity ligation assay showed a localization of Kv7.4 with A-kinase anchoring protein in both vessels in the basal state, which increased only in the RA with isoproterenol stimulation. In the MA, but not the RA, a localization of Kv7.4 with both Rap1a and Rap2 (downstream of EPAC) increased with isoproterenol stimulation. CONCLUSIONS: EPAC-dependent vasorelaxations occur in part via activation of Kv7 channels. This contributes to the isoproterenol-mediated relaxation in mesenteric, but not renal, arteries.
OBJECTIVE: To establish the role of Kv7 channels in EPAC (exchange protein directly activated by cAMP)-dependent relaxations of the rat vasculature and to investigate whether this contributes to β-adrenoceptor-mediated vasorelaxations. APPROACH AND RESULTS: Isolated rat renal and mesenteric arteries (RA and MA, respectively) were used for isometric tension recording to study the relaxant effects of a specific EPAC activator and the β-adrenoceptor agonist isoproterenol in the presence of potassium channel inhibitors and cell signaling modulators. Isolated myocytes were used in proximity ligation assay studies to detect localization of signaling intermediaries with Kv7.4 before and after cell stimulation. Our studies showed that the EPAC activator (8-pCPT-2Me-cAMP-AM) produced relaxations and enhanced currents of MA and RA that were sensitive to linopirdine (Kv7 inhibitor). Linopirdine also inhibited isoproterenol-mediated relaxations in both RA and MA. In the MA, isoproterenol relaxations were sensitive to EPAC inhibition, but not protein kinase A inhibition. In contrast, isoproterenol relaxations in RA were attenuated by protein kinase A but not by EPAC inhibition. Proximity ligation assay showed a localization of Kv7.4 with A-kinase anchoring protein in both vessels in the basal state, which increased only in the RA with isoproterenol stimulation. In the MA, but not the RA, a localization of Kv7.4 with both Rap1a and Rap2 (downstream of EPAC) increased with isoproterenol stimulation. CONCLUSIONS: EPAC-dependent vasorelaxations occur in part via activation of Kv7 channels. This contributes to the isoproterenol-mediated relaxation in mesenteric, but not renal, arteries.
Authors: Sribalaji Lakshmikanthan; Bartosz J Zieba; Zhi-Dong Ge; Ko Momotani; Xiaodong Zheng; Hayley Lund; Mykhaylo V Artamonov; Jason E Maas; Aniko Szabo; David X Zhang; John A Auchampach; David L Mattson; Avril V Somlyo; Magdalena Chrzanowska-Wodnicka Journal: Arterioscler Thromb Vasc Biol Date: 2014-05-01 Impact factor: 8.311
Authors: Preet S Chadha; Friederike Zunke; Hai-Lei Zhu; Alison J Davis; Thomas A Jepps; Søren P Olesen; William C Cole; James D Moffatt; Iain A Greenwood Journal: Hypertension Date: 2012-02-21 Impact factor: 10.190
Authors: Magdalena Chrzanowska-Wodnicka; Susan S Smyth; Simone M Schoenwaelder; Thomas H Fischer; Gilbert C White Journal: J Clin Invest Date: 2005-03 Impact factor: 14.808
Authors: A Martelli; L Testai; M C Breschi; K Lawson; N G McKay; F Miceli; M Taglialatela; V Calderone Journal: Pharmacol Res Date: 2013-01-01 Impact factor: 7.658
Authors: Sean P Nassoiy; Favin S Babu; Heather M LaPorte; Kenneth L Byron; Matthias Majetschak Journal: Clin Exp Pharmacol Physiol Date: 2018-04-27 Impact factor: 2.557
Authors: Yoshinori Nishijima; Ankush Korishettar; Dawid S Chabowski; Sheng Cao; Xiaodong Zheng; David D Gutterman; David X Zhang Journal: Microcirculation Date: 2018-01 Impact factor: 2.628
Authors: Jun Ho Lee; Mee Ree Chae; Su Jeong Kang; Hyun Hwan Sung; Deok Hyun Han; Insuk So; Jong Kwan Park; Sung Won Lee Journal: Pflugers Arch Date: 2020-01-09 Impact factor: 3.657
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Jennifer van der Horst; Rian W Manville; Katie Hayes; Morten B Thomsen; Geoffrey W Abbott; Thomas A Jepps Journal: Arterioscler Thromb Vasc Biol Date: 2020-03-19 Impact factor: 8.311
Authors: Vincenzo Barrese; Jennifer B Stott; Hericka B Figueiredo; Aisah A Aubdool; Adrian J Hobbs; Thomas A Jepps; Alister J McNeish; Iain A Greenwood Journal: Hypertension Date: 2018-04-23 Impact factor: 10.190